Results from a phase 3 trial show that tezepelumab statistically significantly reduced the size of nasal polyps and congestion in CRSwNP.

In sarcoidosis, elevated inflammatory proteins in plasma are evident years before the onset of disease, according to study findings published in the European Respiratory Journal.